278 related articles for article (PubMed ID: 26041667)
1. A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.
Mawatari M; Isoda A; Miyazawa Y; Sawamura M; Matsumoto M
Transpl Infect Dis; 2015 Aug; 17(4):544-50. PubMed ID: 26041667
[TBL] [Abstract][Full Text] [Related]
2. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
4. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.
Kamber C; Zimmerli S; Suter-Riniker F; Mueller BU; Taleghani BM; Betticher D; Zander T; Pabst T
Bone Marrow Transplant; 2015 Apr; 50(4):573-8. PubMed ID: 25599166
[TBL] [Abstract][Full Text] [Related]
5. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
6. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
7. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
[TBL] [Abstract][Full Text] [Related]
8. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
Rogers JE; Cumpston A; Newton M; Craig M
Transpl Infect Dis; 2011 Oct; 13(5):480-4. PubMed ID: 21615848
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
11. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
[TBL] [Abstract][Full Text] [Related]
12. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.
Bilgrami S; Chakraborty NG; Rodriguez-Pinero F; Khan AM; Feingold JM; Bona RD; Edwards RL; Dorsky D; Clive J; Mukherji B; Tutschka PJ
Bone Marrow Transplant; 1999 Mar; 23(5):469-74. PubMed ID: 10100561
[TBL] [Abstract][Full Text] [Related]
13. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
[TBL] [Abstract][Full Text] [Related]
14. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
16. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
[TBL] [Abstract][Full Text] [Related]
17. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.
Koc Y; Miller KB; Schenkein DP; Griffith J; Akhtar M; DesJardin J; Snydman DR
Biol Blood Marrow Transplant; 2000; 6(1):44-9. PubMed ID: 10707998
[TBL] [Abstract][Full Text] [Related]
18. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
19. The effect of varicella-zoster virus reactivation on the long-term outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation.
Li P; Li J; Huang H; Chen X; Lin Y; He G; Xu D
J Health Popul Nutr; 2023 Oct; 42(1):105. PubMed ID: 37784192
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
